Navigation Links
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Date:2/20/2008

EMERYVILLE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales by Merz and its marketing partners of Memantine for the treatment of moderate-to-severe Alzheimer's disease for the quarter ended September 30, 2007. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners.

Paul E. Freiman, President and CEO of Neurobiological Technologies said, "This royalty payment helps provide funding for our ongoing clinical program for Viprinex(TM) (ancrod) and contributes to our strong financial position."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline also includes a drug candidate in early-stage development for Huntington's Disease.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including our dependence on Merz and its marketing partners and risks relating to our ongoing discussions regarding a possible amendment to our marketing agreement with Merz, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission.

Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Despite the volatility that continues to ... Today,s pre-market research on ActiveWallSt.com directs the investor community,s focus ... RDUS ), Cerus Corp. (NASDAQ: CERS ), ... Prime Therapeutics Inc. (NASDAQ: FPRX ). Register with ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... Bangkok, Thailand (PRWEB) , ... May 25, 2016 ... ... the participation of a Thai delegation at BIO 2016 in San Francisco. Located ... private sector will be available to answer questions and discuss the Thai biotechnology ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... WEDI, the ... information exchange, today announced that Charles W. Stellar has been named by the WEDI ... CEO since January 2016. As an executive leader with more than 35 years of ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth ... held The Future of San Diego Life Science event at the Estancia La Jolla ... attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):